A Phase 1 Study to Evaluate the Pharmacokinetics of NEX-22A in Subjects with Type 2 Diabetes Mellitus

The primary objective of this Phase 1 study is to assess the **pharmacokinetics** of NEX-22A in subjects with **Type 2 diabetes**. Understanding the pharmacokinetics is clinically relevant as it provides critical information on the absorption, distribution, metabolism, and excretion of the drug, which is essential for determining appropriate dosing regimens and ensuring safety and efficacy in this patient population.

The clinical trial involves participants diagnosed with **Type 2 diabetes**. The study population includes both male and female subjects, with an age range spanning from adults to the elderly. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any specific lifestyle considerations such as diet or physical activity, have not been disclosed. The absence of detailed inclusion or exclusion criteria suggests a broad approach to participant selection, although specific criteria may exist but are not specified in the available data.

The clinical trial is designed to evaluate the **pharmacokinetics** of NEX-22A in subjects diagnosed with **Type 2 diabetes**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is scheduled to commence recruitment on April 16, 2024, with an estimated completion date of May 13, 2025, indicating an overall duration of approximately 13 months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are designed to monitor the participants' health status, adherence to the study protocol, and any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the pharmacokinetics of NEX-22A.

The expected length of participant involvement in the trial is contingent upon the study's timeline, with each participant's duration varying based on their enrollment date. Conditions that may lead to early termination from the study include non-compliance with the study protocol, withdrawal of consent, or the occurrence of significant adverse events that compromise participant safety. The trial's design and procedures are meticulously crafted to ensure the collection of high-quality data while prioritizing participant safety and ethical standards.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on April 16, 2024, with an estimated end date of May 13, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's objective is to provide robust data on the efficacy of the intervention under investigation, adhering to the rigorous standards expected in a Phase 3 clinical trial.